BD Life Sciences-Biosciences, a segment of BD (Becton, Dickinson, and Company), hosted a two-day workshop at Christian Medical College (CMC) Vellore to enhance knowledge-sharing among laboratory professionals. The event focused on technological advancements and best practices in the assessment of Minimal Residual Disease (MRD) in Acute Leukemia and Myeloma. As per the press release, nearly 75 participants from across India, the Philippines, and Australia attended the workshop, where leading experts from renowned medical colleges and hospitals shared their insights on the technical and analytical aspects of MRD assessment.
Expert Insights on Flow Cytometry and MRD Detection
Commenting on the initiative, Atul Grover, Managing Director of BD India/South Asia, highlighted the crucial role of flow cytometry in clinical applications. He stated, “Flow cytometry has proven to be an invaluable asset in detecting Minimal Residual Disease. This workshop provided laboratory personnel with a platform to access best practices and stay updated on technological advancements. At BD, we strive to introduce clinical technologies that enhance patient outcomes. This aligns with our purpose of Advancing the World of Health.”
Understanding Minimal Residual Disease (MRD)
MRD refers to the small number of cancer cells that remain in the body after treatment. A positive MRD test indicates the presence of residual cancer cells, suggesting a risk of relapse. Doctors use MRD monitoring to evaluate treatment effectiveness, predict patient prognosis, and detect early signs of cancer recurrence. By closely tracking MRD levels, healthcare professionals can confirm remission and optimize treatment strategies.
The Role of Flow Cytometry in MRD Detection
Flow cytometry is a powerful tool for sorting, separating, and analyzing microscopic particles, including cells and chromosomes. It plays a crucial role in clinical diagnostics and research, particularly in Leukemia/Lymphoma phenotyping, stem cell research, immunology, and CD4 testing. BD continues to expand its portfolio of flow cytometry instruments. This empowers clinicians and researchers to make more precise and informed decisions in managing hematological malignancies.
Enhancing Hematopathology Practices
Accurately monitoring chemotherapy response and remission depth is critical in managing patients with hematological cancers. Practicing hematopathologists must understand the prognostic and therapeutic significance of MRD results while keeping pace with advancements in this field. These workshops help improve diagnostic accuracy and patient outcomes. They also reinforce BD’s commitment to advancing healthcare through innovation and education.